Study of Trimedyne's New Side Firing Laser Fiber Shows Faster Tissue Vaporization Results1 February 2007
TRIMEDYNE, INC. (OTCBB: TMED) today announced a small, canine (dog) study of the Company's new side firing laser fiber versus two competitive laser fibers was conducted by Richard A. Santucci, M.D., Associate Professor of Medicine at Wayne State University Medical School in Detroit, Michigan and Chief of Urology at Detroit Receiving Hospital. In the opinion of Dr. Santucci, although the devices were tested on only three dogs and their prostates were small, Trimedyne's new laser fiber vaporized their prostates about 20% faster than laser fibers marketed by Lumenis, Ltd. and American Medical Systems Holdings, Inc. (formerly by Laserscope, Inc.). Trimedyne's new side firing fiber has already been cleared for sale by the FDA.
Trimedyne's new side firing fiber will be marketed in the U.S. and Japan by Boston Scientific Corporation and throughout the rest of the world by Lumenis, Ltd. under Lumenis' DuraMax trademark for use as an accessory to their Holmium lasers for the treatment of enlarged prostates in men, technically benign prostatic hyperplasia or BPH. This condition affects about 50% of men over age 55, and its incidence increases at older ages. The market for treating the approximately 1.2 million BPH cases occurring worldwide annually is estimated at more than $700 million per year.
Shipments of the new fiber to Boston Scientific and Lumenis are expected to commence when they complete their review of Trimedyne's manufacturing and quality processes and testing of the new laser fiber, which is presently anticipated to occur late in the second calendar quarter of 2007.
Trimedyne expects to commence marketing a similar side firing laser fiber under its VaporMAX® trademark for use as an accessory to its 80 watt OmniPulse MAX® Holmium Lasers for the treatment of BPH at about the same time.
Trimedyne manufactures proprietary Holmium lasers and patented fiber optic laser devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial and other information, please visit Trimedyne's website, http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect," "may," "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's Form 10-K-SB for the year ended September 30, 2006 and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 jrudner@trimedyne.com
SOURCE: Trimedyne, Inc.
Source: marketwire
All trademarks and copyrighted information contained herein are the property of their respective owners.
|
